Has economics overshadowed our clinical approaches to EPO?
Sullivan
John D
JD
Boston University, USA.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D003363:Cost Control; D011307:Drug Prescriptions / Q000191:economics; D004363:Drug Utilization; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use; D006397:Hematinics / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008485:Medical Audit; D006278:Medicare / Q000458:organization & administration; D009398:Nephrology / Q000458:organization & administration; D017063:Outcome Assessment, Health Care / Q000458:organization & administration; D011994:Recombinant Proteins; D012051:Reimbursement Mechanisms / Q000458:organization & administration*; D014481:United States
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa